GSK785
GSK785 is a BRD2/4-selective, BRD3-sparing bivalent BET inhibitor. GSK785 inhibits production of the MCP1 cytokine in human whole blood. GSK785 can be used for the research of cancer.
For research use only. We do not sell to patients.
- CAS No.: 3125088-67-4
- Formula: C33H38N4O3
- Molecular Weight:538.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
BRD2 |
BRD4 |
BET |
In Vitro
GSK785 (Compound 9h) (Titrated 1:3 from 1 mM stock in 100% DMSO; 18-24 h) inhibits BRD2, BRD3, and BRD4 in HEK 293 WT cells with pIC50 values of 7.9, 6.9, and 8.5, respectively, showing BRD2/4 selectivity and BRD3 sparing[1].
GSK785 (Titrated 1:3 from 1 mM stock in 100% DMSO; 4 h) binds bivalently to BRD4 in HEK 293 WT cells with a pIC50 of 7.9 in the BRD4 Biosensor assay[1].
GSK785 (1.6 nM-5 μM; 2 h) stabilizes BRD2, BRD3, and BRD4 in HuT 78 cells with pEC50 values of 8.1, 6.0, and 7.0, respectively, confirming BRD2/4 selectivity and BRD3 sparing[1].
GSK785 inhibits production of the MCP1 cytokine in human whole blood with an pIC50 of 7.4[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 3125088-67-4
-
Molecular Weight 538.68
-
Formula C33H38N4O3
-
SMILES
C[C@@H]1C2=CC=C(C=C2C=CN(C1=O)C)CN3CCC4(CC3)CN(C(C5=CC=C6[C@H](C(N(C=CC6=C5)C)=O)C)=O)C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)